Advanced non-small cell lung cancer
Conditions
Interventions
The monotherapy or combination therapy group of immune checkpoint inhibitors:None
Sponsors
Zhongshan People’s Hospital
Eligibility
Sex/Gender
All
Age
75 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. The tissue pathology was diagnosed as NSCLC. 2. Those patients with clinical stage IIIB, IIIC or IV who are not suitable for surgery or radiotherapy; 3. Age 75 or above before receiving first-line treatment. 4. The first-line treatment options are chemotherapy or receiving adjuvant chemotherapy for more than half a year, and no immunotherapy has been used previously.
Exclusion criteria
Exclusion criteria: 1. Combine history of other types of cancer. 2. There is a lack of effective information for evaluating the efficacy and conducting follow-up. 3. Patients with incomplete data. 4. Patients who have undergone first-line systemic treatment for epidermal growth factor receptor gene mutations (EGFR) and anaplastic lymphoma kinase (ALK) rearrangement, or who received first-line systemic treatment with molecular targeted drugs (excluding anti-angiogenic drug therapy), were excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Progression-free survival period;Overall survival period; | — |
Countries
China
Contacts
Public ContactJunkai Zhang
Zhongshan People’s Hospital
Outcome results
None listed